Caveats: -secondary analysis (consider exploratory) -unclear clinical significance (modest ΔeGFR) -baseline CrCl 40+ (do NOT use in advanced CKD) -systemic rheumatic diseases excluded (unethical to randomize to PBO for 2 years) -generalizability (all had CVD, M>F, mean age 66)